+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P10215(TRO Antibody) at dilution 1/65. (Original magnification: ×200)    

  
  

TRO antibodies, targeting the TROP2 (Trophoblast cell surface antigen 2) protein, have gained prominence in cancer research and therapy. TROP2 is a transmembrane glycoprotein overexpressed in various epithelial cancers, including breast, lung, and pancreatic tumors. Initially identified in trophoblast cells, it regulates cell signaling, adhesion, and proliferation, often linked to aggressive tumor behavior and poor prognosis.

The development of TROP2-targeted therapies, particularly antibody-drug conjugates (ADCs), marks a breakthrough. Sacituzumab govitecan, an ADC combining a TRO antibody with a cytotoxic payload, was FDA-approved for metastatic triple-negative breast cancer and urothelial carcinoma. These therapies exploit TROP2 overexpression on cancer cells to deliver precise, tumor-specific cytotoxicity while sparing healthy tissues.

Research also explores TRO antibodies in diagnostic applications, leveraging their specificity to detect TROP2 in tumor biopsies. Despite successes, challenges remain, such as managing off-target effects and understanding resistance mechanisms. Ongoing studies aim to refine antibody design and expand therapeutic indications, positioning TRO antibodies as pivotal tools in oncology. Their dual role in targeting and diagnostics underscores their transformative potential in personalized cancer care.